Serum levels of intact parathyroid hormone is a prognostic indicator of dialyzed patients: the Nishinomiya study

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in this observational study publication.

To investigate the impact of this iPTH target on CVD, dialysis patients were enrolled.

Why It Was Studied

Patients with chronic kidney disease on dialysis are at higher risk for cardiovascular disease (CVD), which is the greatest cause of mortality.

The target range of serum intact parathyroid hormone (iPTH) for prognosis, 60 to 240 pg/mL, was recommended by the Japanese Society for Dialysis Therapy guidelines.

Who Took Part

The abstract describes 287 participants taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

At the start of the study, serum iPTH levels, routine laboratory parameters, and certain factors related to CVD were evaluated.

What Was Measured

Patients with chronic kidney disease on dialysis are at higher risk for cardiovascular disease (CVD), which is the greatest cause of mortality.

The subject headings attached to it are Cardiovascular Diseases, Cohort Studies, Japan, Kaplan-Meier Estimate, Parathyroid Hormone, Practice Guidelines as Topic and Prognosis.

The authors tagged it with the keywords Chronic kidney disease, Dialysis and Intact parathyroid hormone.

What This Means in Plain Language

This is an observational study of Parathyroid Hormone (PTH 1-84) in 287 participants.

The publication is from 2014 (Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy), a journal based in Australia.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.